問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

馮盈勳

Recruiting

List

66Cases

2022-02-16 - 2026-12-31

Others

Active
A Randomized, Double-Blind, Multi-Center Study of ADI-PEG 20 Versus Placebo in Subjects With Genotype WWOX-GG, Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma Advanced Hepatocellular Carcinoma

  • Test Drug

    ADI-PEG 20

Participate Sites
9Sites

Recruiting9Sites

2022-04-01 - 2026-12-31

Phase II

A Phase 2 Study to Evaluate the Safety and Immunological Efficacy of Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients with HER2 Expressing Gastric Cancer (CORNERSTONE-003)

  • Condition/Disease

    Stomach cancer

  • Test Drug

    AST 301/pNGVL3 hICDLEUKINE® (sargramostim)

Participate Sites
6Sites

Recruiting6Sites

2021-07-01 - 2022-08-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting2Sites

Terminated1Sites

2019-05-01 - 2025-12-31

Phase I/II

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer

  • Condition/Disease

    Advance tumor

  • Test Drug

    FLX475

Participate Sites
4Sites

Recruiting4Sites

2022-03-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-08-01 - 2029-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-05-01 - 2025-06-30

Phase III

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With an Aromatase Inhibitor

  • Condition/Disease

    advanced or metastatic breast cancer

  • Test Drug

    Capivasertib

Participate Sites
9Sites

Recruiting9Sites

2023-08-01 - 2036-12-31

Phase III

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

  • Condition/Disease

    Breast Cancer, Early Breast Cancer

  • Test Drug

    Camizestrant (AZD9833)

Participate Sites
8Sites

Recruiting8Sites

2015-12-01 - 2026-12-31

Phase II

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
8Sites

Recruiting8Sites

2019-06-01 - 2025-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB